Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
作者信息
Bentham P, Gray R, Sellwood E, Raftery J
出版信息
BMJ. 1999 Sep 4;319(7210):640-1. doi: 10.1136/bmj.319.7210.640a.
Abstract
摘要
相似文献
1
Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
BMJ. 1999 Sep 4;319(7210):640-1. doi: 10.1136/bmj.319.7210.640a.
2
Rivastigmine in the treatment of Alzheimer's disease.
Eur Neurol. 2001;46(2):110. doi: 10.1159/000050779.
3
Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
Int J Clin Pract. 2002 Jul-Aug;56(6):414-5.
4
Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
Int J Geriatr Psychiatry. 1999 Dec;14(12):1078-9. doi: 10.1002/(sici)1099-1166(199912)14:12<1078::aid-gps73>3.0.co;2-s.
5
Rivastigmine for Alzheimer's disease.
Drug Ther Bull. 2000 Feb;38(2):15-6.
6
FDA approves new cholinesterase inhibitor for Alzheimer's disease.
Am J Health Syst Pharm. 2000 Jun 1;57(11):1026, 1028. doi: 10.1093/ajhp/57.11.1026.
7
Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed.
BMJ. 1999 Sep 4;319(7210):641-2.
8
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
Pharmacoeconomics. 2000 Dec;18(6):609-12. doi: 10.2165/00019053-200018060-00007.
9
Effectiveness of rivastigmine in Alzheimer's disease. Guidelines do not ignore clinically relevant end points.
BMJ. 1999 Sep 4;319(7210):642.
10
Alzheimer's disease: translating neurochemical insights into clinical benefits.
J Clin Psychiatry. 2000 Oct;61(10):791-802. doi: 10.4088/jcp.v61n1012.
引用本文的文献
1
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
2
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2021 Jan 12;51(1):8-58.
3
Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.
Biomolecules. 2019 Dec 26;10(1):40. doi: 10.3390/biom10010040.
4
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95. doi: 10.1136/jnnp.71.5.589.
5
Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Pharmacoeconomics. 2001;19(3):303-18. doi: 10.2165/00019053-200119030-00008.
6
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
BMJ. 2000 Dec 9;321(7274):1445-9. doi: 10.1136/bmj.321.7274.1445.
7
本文引用的文献
1
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs.
Seizure. 1999 Feb;8(1):8-13. doi: 10.1053/seiz.1998.0248.
2
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
BMJ. 1999 Mar 6;318(7184):633-8. doi: 10.1136/bmj.318.7184.633.
3
Acetylcholinesterase inhibitors for Alzheimer's disease.
BMJ. 1999 Mar 6;318(7184):615-6. doi: 10.1136/bmj.318.7184.615.
4
First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.
Alzheimer Dis Assoc Disord. 1998 Dec;12(4):266-80. doi: 10.1097/00002093-199812000-00006.
5
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
JAMA. 1994 Apr 6;271(13):985-91.
6
Measurement of quality-of-life changes in patients with Alzheimer's disease.
Clin Ther. 1989 Jul-Aug;11(4):545-54.
Zotero 插件